临床试验状态

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

登记停止说明（原文）：The study was withdrawn because the pharmaceutical sponsor withdrew support for the study. No participants were enrolled before termination.

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

登记停止说明（原文）：recruitment challenges

Phenobarbital for Agitated Delirium

登记停止说明（原文）：Not approved by IRB

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

登记停止说明（原文）：protocol amendment

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

登记停止说明（原文）：Lack of funding

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

登记停止说明（原文）：Business reasons and not based on any safety concerns.

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

登记停止说明（原文）：Halted prematurely

Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine

登记停止说明（原文）：The study was terminated early due to operational feasibility challenges, including multi-site coordination and administrative barriers. The study team determined continuation was not feasible, and all study activities were discontinued.

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

登记停止说明（原文）：The study was terminated early due to a strategic business decision by the Sponsor, unrelated to safety.

CT-95 in Advanced Cancers Associated With Mesothelin Expression

登记停止说明（原文）：The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.

Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

登记停止说明（原文）：Re-formulation of study product needed.

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

登记停止说明（原文）：Due to extremely low accrual rate

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

登记停止说明（原文）：FDA Clinical Hold

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

登记停止说明（原文）：inability to recruit volunteers

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

登记停止说明（原文）：The primary reasons for early study termination are administrative and funding issues and inability to obtain the investigational product; this lead to insufficient participant enrollment.

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

登记停止说明（原文）：Sponsor decision based on meeting essential enrollment and obtaining substantial data to support future pancreatic ductal adenocarcinoma (PDAC) trials in a first-line setting.

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

登记停止说明（原文）：Change in standard of care treatment for muscle-invasive bladder cancer